Filtered By:
Source: Stroke
Condition: Hypertension
Drug: Pradaxa

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients Clinical Sciences
Conclusions— All the newer oral anticoagulants compared were more effective than adjusted dosed warfarin. Our model showed that apixaban was the most effective anticoagulant in a general atrial fibrillation population and has an incremental cost-effectiveness ratio <$50 000/QALY. For those with higher stroke risk (CHADS2≥3), dabigatran was the most cost-effective treatment option.
Source: Stroke - May 22, 2016 Category: Neurology Authors: Shah, A., Shewale, A., Hayes, C. J., Martin, B. C. Tags: Anticoagulants, Cost-Effectiveness, Ischemic Stroke Clinical Sciences Source Type: research

Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control Clinical Sciences
Conclusions— In Chinese patients with atrial fibrillation, the benefits of warfarin therapy for stroke prevention and ICH risk are closely dependent on the quality of anticoagulation, as reflected by TTR. Even at the top TTR quartile, warfarin was associated with a higher stroke and ICH risk than dabigatran.
Source: Stroke - December 22, 2014 Category: Neurology Authors: Ho, C.-W., Ho, M.-H., Chan, P.-H., Hai, J.-J., Cheung, E., Yeung, C.-Y., Lau, K.-K., Chan, K.-H., Lau, C.-P., Lip, G. Y. H., Leung, G. K.-K., Tse, H.-F., Siu, C.-W. Tags: Coumarins, Other anticoagulants, Anticoagulants Clinical Sciences Source Type: research